Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
- Conditions
- Inoperable Early Stage Non-small Cell Lung Cancer
- Registration Number
- NCT01138748
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival.
The current trial addresses the issue if progression free survival (PFS) in patients treated with radiotherapy can be predicted by a multi-variate model derived from a composite of bio-imaging and biomarkers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 5
- Proof of cT1a/b - 2a/b N0M0 NSCLC
- Informed Consent signed
- Resectable tumour
- > 18 years old
- men and women
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method development and validation of a multi-variate predictive model from 2 to 5 years To develop and validate a multi-variate predictive model based on bio-imaging and biomarkers for progression)free survival from 2 to 5 years.
- Secondary Outcome Measures
Name Time Method the clinical response and complication rate from 2 to 5 years local, regional or distant failure from 2 to 5 years progression free survival from 2 to 5 years disease specific overall survival from 2 to 5 years
Trial Locations
- Locations (1)
University Hospital Ghent
🇧🇪Ghent, Belgium
University Hospital Ghent🇧🇪Ghent, Belgium